| Catalogue No. |
R-1145-100 |
| Description |
Glial Fibrillary Acidic Protein (GFAP) is a 50 kDa intra-cytoplasmic filamentous protein of the cytoskeleton in astrocytes. During the development of the central nervous system, it is a cell-specific marker that distinguishes astrocytes from other glial cells. GFAP immunoreactivity has been shown in immature oligodendrocytes, epiglottic cartilage, pituicytes, papillary meningiomas, myoepithelial cells of the breast and in non-CNS: Schwann cells, salivary gland neoplasms, enteric glia cells, and metastasizing renal carcinomas. At least 3 isoforms are produced from alternate splicing. These isoforms differ in the C-terminal region which is encoded by alternative exons. |
| Batch No. |
See product label |
| Unit size |
100 ug |
| Antigen |
A synthetic peptide (EMARHLQEYQDLLNVK) corresponding to a region (341-356) from human Glial Fibrillary Acidic Protein. To enhance the immunological response, this peptide was coupled to carrier protein BSA. |
| Other Names |
Astrocyte; Glial fibrillary acidic protein; GFAP; |
| Accession |
P14136 GFAP_HUMAN; |
| Produced in |
Rabbit |
| Purity |
Affinity purified on antigen column |
| Applications |
Immunohistochemistry (IHC) and Western Blotting (WB). A concentration of 1.0 ug/mL is recommended for WB. Human GFAP has a predicted length of 432 residues and MW of 50 kDa. A concentration of 2.0 ug/mL is recommended to detect GFAP in formalin fixed and paraffin embedded tissues. Heat mediated antigen retrieval is required. Biosensis recommends optimal dilutions/concentrations should be determined by the end user. |
| Specificity |
The specificity of this antibody has been confirmed by WB and IHC against the antigen. |
| Cross-reactivity |
Human; rat; predicted to react with mouse due to sequence homology; |
| Blast it |
If you wish to use this product in a species other than those specified here and want to determine the amino acid sequence homology between the immunogen and the corresponding protein in that species, simply copy the amino acid sequence for this immunogen and test it on the BLAST database that you can access through the link below. Please note that antibodies raised against synthetic peptides are quite often very specific for that peptide. What this means in practise is that a single amino acid difference may be enough to restrict the specificity to a particular molecule. The BLAST database can also be used to compare any amino acid sequence between species and between protein. The full amino acid sequence of the target protein can be found by following the link in the Accession field. You can then search any amino acid sequence in the target protein using the BLAST database. When selecting a sequence to search, please choose carefully, as the sequence you choose may be a precursor rather than the mature protein for example. |
| Form |
Lyophilized from 1.2% sodium acetate, 2mg BSA, 0.2mg NaN3 |
| Reconstitution |
Reconstitute in 1 mL of PBS (pH 7.4) to achieve an antibody concentration of 100 ug/mL. Centrifuge to remove any insoluble material. |
| Storage |
At least 12 months after purchase at 2-8C (lyophilized formulations). After reconstitution, aliquot and store at -20C for a higher stability. Avoid freeze-thaw cycles. |
| Expiry Date |
12 months after purchase. |
| References |
1. Reeves S.A, et al. Proc. Natl. Acad. Sci. U.S.A. 86:5178-5182(1989).
2. Brenner M, et al. Brain Res. Mol. Brain Res. 7:277-286(1990).
2. Isaacs A, et al. Genomics 51:152-154(1998).
3. Ota T, et al. Nat. Genet. 36:40-45(2004).
4. Nielsen A.L, et al. J. Biol. Chem. 277:29983-29991(2002).
5. Singh R, et al. Genomics 82:185-193(2003).
6. Brenner M, et al. Nat. Genet. 27:117-120(2001).
7. Brockmann K, et al. Eur. Neurol. 50:100-105(2003).
8. Stumpf E, et al. Arch. Neurol. 60:1307-1312(2003).
9. Sawaishi Y, et al. Neurology 58:1541-1543(2002).
10. Aoki Y, et al. Neurosci. Lett. 312:71-74(2001).
|
